AUPH - Aurinia Pharmaceuticals Inc.
| Previous Close | 6.89 |
| Open | 6.96 |
| Bid | 6.83 x 800 |
| Ask | 6.85 x 900 |
| Day's Range | 6.75 - 7.07 |
| 52 Week Range | 4.76 - 7.85 |
| Volume | 789,583 |
| Avg. Volume | 890,003 |
| Market Cap | 582.185M |
| Beta (3Y Monthly) | 1.06 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.63 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.92 |
- Benzinga•yesterday
Aurinia's Dry Eye Syndrome Drug Produces Mixed Results In Mid-Stage Trial
Small-cap biotech Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) fell Tuesday morning following the release of clinical trial results. What Happened Aurinia said a mid-stage study that evaluated its dry eye ...
- Business Wire•yesterday
Aurinia Announces Voclosporin Ophthalmic Solution Demonstrates Statistically Superior Efficacy Versus Restasis® in a Phase 2 Head-to-Head Study for the Treatment of Dry Eye Syndrome
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/TSX:AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced positive results for its exploratory Phase 2 head-to-head study evaluating the efficacy, safety and tolerability of voclosporin ophthalmic solution (VOS 0.2%) versus Restasis®(cyclosporine ophthalmic emulsion 0.05%) for the treatment of dry eye syndrome (DES). Both drugs were shown to be well-tolerated and there was no statistical difference between VOS and Restasis® for the primary endpoint as both drugs exhibited low drop discomfort scores.
- Business Wire•2 days ago
Aurinia to Hold Conference Call and Webcast to Discuss Results of Phase 2 Head-to-Head Study of Voclosporin Ophthalmic Solution versus Restasis® for the Treatment of Dry Eye Syndrome
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/TSX:AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced it will report results before the opening of trading and hold a webcast and conference call to discuss the results of its Phase 2, double-masked, head-to-head study of VOS 0.2% versus Restasis® (cyclosporine ophthalmic emulsion 0.05%) to evaluate the efficacy, safety and tolerability at four weeks in subjects with dry eye syndrome (DES). Aurinia will host a conference call and webcast presentation at 8:00am ET on Tuesday, January 22, 2019.
- Zacks•2 days ago
Do Options Traders Know Something About Aurinia Pharmaceuticals (AUPH) Stock We Don't?
Investors need to pay close attention to Aurinia Pharmaceuticals (AUPH) stock based on the movements in the options market lately.
- TheStreet.com•7 days ago
My Rx for How to Buy Aurinia Pharmaceuticals on Its Breakout
In Tuesday's fast-paced Lightning Round of Jim Cramer's "Mad Money" program on CNBC, Jim commented that Aurinia Pharmaceuticals Inc. was "a great speculative stock." Let's check out the charts to see what sort of potential AUPH may have in the months ahead. In this daily bar chart of AUPH, below, we can see that prices broke out on the upside from a year-long sideways consolidation pattern.
- ACCESSWIRE•last month
4 Pharma Stocks Getting a Boost on Thursday (12/20/18)
CORAL GABLES, FL / ACCESSWIRE / December 20, 2018 / The healthcare industry is complicated, this much is certain, but amidst the complexities exist innovative approaches to healthcare that will ultimately provide the best quality of care for patients in the future. From advancements in the nascent telehealth industry to improved treatment options for patients, the healthcare sector may offer significant opportunities in the near future. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Aevi Genomic Medicine, Inc (GNMX), Aurinia Pharmaceuticals, Inc (AUPH), and CV Sciences, Inc (CVSI) are 4 pharma stocks to pay attention to heading into the rest of the week.
- Business Wire•last month
Aurinia to Present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco
Aurinia Pharmaceuticals Inc., today announced its Chairman and Chief Executive Officer, Richard M. Glickman, will present a company overview at the 37th Annual J.P.
- Business Wire•2 months ago
Aurinia Establishes at-the-Market Facility
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”) today announced that it has entered into an Open Market Sale Agreement (the “Sale Agreement”) with Jefferies LLC (“Jefferies”) pursuant to which the Company may from time to time sell, through at-the-market (“ATM”) offerings with Jefferies acting as sales agent or directly to Jefferies acting as principal, such common shares in the capital of the Company (“Common Shares”) as would have an aggregate offering price of up to US$30,000,000. Aurinia has also filed a prospectus supplement with securities regulatory authorities in Canada in the provinces of British Columbia, Alberta and Ontario, and with the United States Securities and Exchange Commission, which supplements Aurinia’s short form base shelf prospectus dated March 26, 2018, and Aurinia’s shelf registration statement on Form F-10 dated March 26, 2018, declared effective on March 29, 2018.
- GlobeNewswire•2 months ago
Analysis: Positioning to Benefit within Abeona Therapeutics, Great Lakes Dredge & Dock, Imprimis Pharmaceuticals, Alliant Energy, Cytokinetics, and Aurinia Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Business Wire•2 months ago
Aurinia to Participate in November Investor Conferences
Aurinia Pharmaceuticals Inc., today announced its Chairman and CEO, Richard Glickman, will participate in two upcoming investor conferences.
- Zacks•2 months ago
Aurinia Pharmaceuticals (AUPH) Reports Q3 Loss, Tops Revenue Estimates
Aurinia (AUPH) delivered earnings and revenue surprises of -23.53% and 476.92%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•2 months ago
Aurinia: 3Q Earnings Snapshot
The Victoria, British Columbia-based company said it had a loss of 21 cents per share. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
- Business Wire•2 months ago
Aurinia Reports Third Quarter Financial Results, Clinical Highlights and Corporate Development
VICTORIA, British Columbia-- -- AURORA Phase III Trial in lupus nephritis completes enrollment ahead of schedule Phase II data for the treatment of dry eye expected in January 2019 Phase II FSGS Trial ongoing Richard M. Glickman announces his intention to retire as CEO next year, upon identification and appointment of an appropriate successor Aurinia Pharmaceuticals Inc. has released its financial ...
- Business Wire•3 months ago
Aurinia Pharmaceuticals to Release Third Quarter Financial Results and General Business Updates on November 8, 2018
Conference Call and webcast to follow
- Motley Fool•4 months ago
Here's What Pushed Aurinia Pharmaceuticals Inc. Up 16.8% in September
Steady progress for the company's experimental lupus treatment took an important step forward
- Zacks•4 months ago
Aurinia Pharmaceuticals (AUPH) in Focus: Stock Moves 6.7% Higher
Aurinia Pharmaceuticals (AUPH) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
- Benzinga•4 months ago
The Daily Biotech Pulse: Verastem's Chinese Duvelisib Licensing Deal, Aldeyra's Positive Dry Eye Disease Drug Trial
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Sept. 25) Abbott Laboratories (NYSE: ABT ) Amarin Corporation ...
- Business Wire•4 months ago
Aurinia Completes Enrollment of AURORA, its Phase 3 Clinical Trial for the Treatment of Lupus Nephritis
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH/TSX:AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced that it has completed enrollment for the AURORA Phase 3 trial ahead of schedule. The target enrollment of 324 patients was surpassed due to high patient demand with 358 lupus nephritis (LN) patients randomized in sites across 27 countries. “We are elated by the significant interest this trial has garnered around the globe, which reinforces the need for new treatment options for patients living with lupus nephritis,” said Richard M. Glickman, Aurinia’s Chairman and Chief Executive Officer.
- Business Wire•4 months ago
Aurinia to Participate in Upcoming Investor Conferences
Aurinia Pharmaceuticals Inc., today announced its Chairman and CEO, Richard Glickman, will present a company overview at two upcoming investor conferences.
- Business Wire•5 months ago
Aurinia Announces Participation at the 20th Annual Global Investment Conference in New York City September 4-6, 2018
Aurinia Pharmaceuticals Inc., (AUPH)(AUP.TO) today announced it will be featured as a presenting company at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held on September 4-6, 2018 at the St. Regis New York Hotel in New York City. Celia Economides, Vice President of Corporate and Public Affairs, will provide an overview of the Company's business on Thursday, September 6 at 10:50am ET. If you are an institutional investor, and would like to attend the Company’s presentation, please click on the following link (www.rodmanevents.com) to register for the conference.
- Zacks•5 months ago
Aurinia Pharmaceuticals (AUPH) Reports Q2 Loss, Tops Revenue Estimates
Aurinia (AUPH) delivered earnings and revenue surprises of -18.75% and 447.17%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•5 months ago
Aurinia: 2Q Earnings Snapshot
The Victoria, British Columbia-based company said it had a loss of 19 cents per share. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
- Business Wire•5 months ago
Aurinia Reports Second Quarter Financial Results and Operational Highlights
AURORA Phase III Trial in lupus nephritis anticipated to complete enrollment ahead of schedule
